Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

nce, noted, "The early data from our antiviral program designed to test the potential of our PS-targeting antibodies to prevent and treat viral hemorrhagic fevers is very encouraging, and we are pleased to have the opportunity to present our findings at this major meeting of our biodefense peers. Results to date are confirming that our PS-targeting antibodies may have broad spectrum potential against multiple viruses, which could make them valuable against both hemorrhagic fever viruses and other biodefense threats. Further efficacy studies are already underway and we look forward to reporting on our progress as we continue to advance this important program."

Researchers also reported that studies are in progress to determine the pharmacokinetics and efficacy of PS-targeting antibodies in additional VHF infection models, as well as to develop lyophilized formulations suitable for an extended shelf life under a variety of storage and shipping conditions. In addition, Peregrine is developing a second-generation, fully human PS-targeting antibody as part of its federally funded antiviral program efforts.

"These positive initial efficacy data after administration of only a single dose is an early confirmation of the potential of our anti-PS antibodies as broad-spectrum therapeutics for VHF," said Steven W. King, president and CEO of Peregrine. "They also reflect the excellent progress being achieved by our multi-institutional project team. This first public presentation of data from our ongoing federally funded program is also consistent with our extensive preclinical and clinical experience showing the broad-spectrum antiviral potential of our PS-targeting technology platform and we look forward to sharing more results from the studies as further progress is made."

Under a major biodefense initiative, bavituximab and a fully human equivalent antibody are in preclinical development for the treatment of viral hemorrhagic fevers un
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ - Aptose Biosciences ... company developing new therapeutics that target the underlying mechanisms ... Drug Administration (FDA) has granted the company orphan drug ... leukemia (AML). APTO-253, a first-in-class inducer of the KLF4 ... Phase Ib clinical trial in patients with AML, high-risk ...
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) ... Market by Product , Test, Application & End User ... The bioburden testing market is expected to ... 2014, growing at a CAGR of 9.8% from 2014 ... microbial limit testing market is segmented into consumables and ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ) has announced ... Market Size, Strategy and Forecasts - 2015 to 2019" ... - Global Market Size, Strategy and Forecasts - 2015 ... use. Hundreds of pages of information including a complete ... Schedules to help understand test pricing in detail. ...
(Date:6/2/2015)... Meet ARGUS, The World,s First Contactless Facial ... Analyze emotions and predict actions. Explore a New Generation ... Responsive-RPG: "The Eye: Genesis".      (Photo: ... https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 Imagine being ... - and those of others. Being able to read ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Bioburden Testing Market 2015 - Global Forecasts to 2019 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3
... International Market Opportunities for the Company,s Medical ... ... PIP ), a biodefense company developing medical countermeasures,against biological and chemical ... a special UK government advisor., Lord Moonie will assist PharmAthene ...
... --,China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ... in the People,s,Republic of China ("PRC"), today announced ... a.m. EDT on Friday, August 15, 2008, to ... in the live conference call, please dial the ...
... Duff & Phelps Corporation,(NYSE: DUF ), a ... announced that it has acquired the Lumin Expert ... specializes in,intellectual property dispute support and expert testimony. ... Lumin performs independent analyses of financial, economic and ...
Cached Biology Technology:Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene 2Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene 3China Biologic Products Announces Second Quarter 2008 Results Conference Call 2Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice 2
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Northwest National Laboratory scientists have used electrostatic attraction ... carbon nanotubes. , This configuration can accommodate ... monitoring to infectious-agent detection, said Yuehe Lin, who ... campus' W.R. Wiley Environmental Molecular Sciences Laboratory. ...
... a vaccine designed to fight avian influenza will begin this ... is part of a multicenter trial that will test a ... whether the vaccine still triggers a strong immune response at ... the National Institute of Allergy and Infectious Diseases of the ...
... online today in the journal Nature Methods, researchers at ... powerful new tool that will facilitate genetic research and ... genetic disease. , The researchers have combined several ... lentiviral vector ?a gene delivery system partly derived from ...
Cached Biology News:A biosensor layered like lasagna 2Duke to test bird flu vaccine dosing 2Swiss researchers develop all-in-one remote control gene expression tool 2
... Rabbit polyclonal to BMP2 BMP2 ... beta (TGFB) superfamily. Bone morphogenic protein ... candidate gene for the autosomal dominant ... Immunogen: Synthetic peptide: ...
... foil heat sealing material is suitable ... a screw down heated lid), especially ... useful method for sample retrieval. Multiple ... existing seal. Ideal for compound management ...
...
...
Biology Products: